Estriol

Estriol is a steroid hormone of the estrogen class, classified as a minor and relatively weak female sex hormone ^[1][2]. Chemically it is an estrane steroid carrying three hydroxyl groups, the source of the "triol" in its name and the "3" in the abbreviation E3 ^[1]. Of the body's three main estrogens, estriol has the lowest potency, binding the estrogen receptors much more weakly than estradiol; it is generally considered to have on the order of a tenth or less of estradiol's activity ^[1][2].

Outside of pregnancy, estriol is present only in trace amounts, but during pregnancy its production rises dramatically, by roughly a thousandfold, because it is synthesized by the placenta from precursor molecules supplied largely by the fetus ^[1]. This fetal-placental origin makes maternal estriol a useful marker of the health of the pregnancy: the level of unconjugated estriol in the mother's blood is one of the components of the "triple" and "quadruple" screening tests used to estimate the risk of conditions such as Down syndrome, although the results can be influenced by other factors and are interpreted alongside additional markers ^[1].

In medicine estriol is used mainly in hormone therapy for the symptoms of menopause, and its weak, more localized activity makes it well suited to vaginal preparations that treat vulvovaginal atrophy, dryness, and related discomfort ^[1][4]. A clinical trial of low-dose estriol vaginal gel in postmenopausal breast-cancer survivors, for instance, found that it improved vaginal symptoms while circulating estrogen levels stayed low ^[4]. Estriol has also drawn research interest beyond gynecology: because it rises during pregnancy, a period when the autoimmune disease multiple sclerosis often quiets down, it has been tested as a treatment for that condition, with early studies reporting reductions in brain lesions and shifts in immune signaling ^[3]. It is available in Europe and some other regions but has not been approved as a stand-alone drug in the United States ^[1].

Estriol was discovered in 1930, isolated from the urine of pregnant women by the biochemist Guy Marrian and colleagues ^[1]. It is formulated as tablets, vaginal creams, gels, pessaries, and rings, most often for local vaginal use ^[1][4]. As with other estrogens, its use is weighed against the general risks of estrogen therapy, though its weakness and the low blood levels achieved with vaginal dosing are thought to limit systemic effects ^[1][4].

Estriol is a prescription hormone in the jurisdictions that license it, and a cream does not confine it to the skin. The absorption mechanism is ordinary passive diffusion: the stratum corneum is a lipid barrier, estriol is a small lipophilic steroid of 288 daltons with no ionisable group at skin pH, so it partitions into that lipid barrier, diffuses through it, and once past the epidermis it reaches the dermal capillary plexus and enters the systemic circulation directly. Nothing on that path passes through the liver, so there is no first pass metabolism to blunt it, which is the whole reason transdermal oestrogen produces a different hormonal and metabolic profile from the same oestrogen swallowed ^[2]; a face cream is that same physics at a smaller dose across a thinner barrier. The amount delivered scales with the concentration applied, the area covered and the vehicle, which is why an occlusive or permeation enhanced base changes the answer.

How much actually crosses is where the honest reading gets uncomfortable. Estriol is the poorest skin permeant of the common steroids in vitro, at 2.45 percent across mouse skin in 16 hours against 18.0 percent for estradiol ^[16], and it is the one that stalls in the epidermis rather than reaching the dermis ^[15]. Applying 1 gram of 0.01 percent estradiol or 0.3 percent estriol ointment to the face daily for three months left serum follicle stimulating hormone, prolactin and estradiol unchanged and vaginal cytology unchanged in seventeen women ^[9], and estriol iontophoresis into acne scars produced no hormonal change ^[19]. But the larger facial trial by the same group reported that prolactin did rise significantly over six months, while treating the absence of other changes as reassuring ^[7], and none of those studies measured serum estriol itself, only estradiol, follicle stimulating hormone and prolactin. A rise in the hormone actually being applied would not have shown up in any of them.

Where serum estriol has been measured directly, by a mucosal rather than a facial route, it rises clearly. An ultra low dose 0.03 mg estriol vaginal tablet raised serum estriol to a peak of 168 picograms per millilitre two to three hours after the first application in 15 of 16 postmenopausal breast cancer patients, still slightly raised in 8 of them at four weeks, while estrone and estradiol did not move at any point ^[36]. A 0.005 percent estriol vaginal gel likewise raised estriol before it normalised by week 12, with estradiol and estrone mostly undetectable ^[4]. Those are vaginal atrophy studies and a different indication from facial skincare, but they establish the fact that matters here: estriol reaching the bloodstream from a topical application is normal and expected, not a sign of misuse.

Compounded and permeation enhanced skin formulations move measurably more. In Franz cells on human skin, an estriol and estradiol combination in a Pentravan base delivered 14.02 micrograms per square centimetre of estriol ^[28]; an anhydrous permeation enhancing base delivered 55 plus or minus 25 nanograms per square centimetre of estriol through human cadaver abdominal skin at 24 hours, against 341 plus or minus 122 for estradiol, with the authors stating plainly that the vehicle delivers these hormones through the skin and into the bloodstream ^[27]; another transdermal vehicle put 48.5 percent of its estriol load through human skin into the receiver compartment ^[29]; and permeation enhancing bases carrying an estradiol and estriol combination behave the same way ^[26]. In a five year single arm study of a nanostructured transdermal formulation carrying 0.1 percent estriol together with 0.25 percent estradiol and 10 percent progesterone applied to the forearm, serum estradiol and follicle stimulating hormone both changed significantly, follicle stimulating hormone falling from 82.04 to 57.12 international units per millilitre, which shows the route works systemically; the estradiol in the same formulation makes it impossible to attribute that to estriol ^[30]. By the oral route, 2 mg of estriol succinate daily raised total estriol by 500 percent without altering unconjugated oestrogens, a reminder that estriol circulates largely conjugated ^[42].

One population level signal exists on cosmetic estriol and it is neither reassuring nor conclusive. Estriol was detected in 73 of 240 skincare products sold in China at a median 34.58 micrograms per gram; dermal application of estriol containing cream raised thyroid peroxidase and thyroglobulin antibodies in nude mice; and a hospital based case control comparison found skincare cosmetic use associated with autoimmune thyroid disease at an odds ratio of 1.577 with a confidence interval of 1.037 to 2.400. In the same paper a population based cross sectional comparison found no difference in antibodies or thyroid function between users and non users, and the authors describe the whole thing as preliminary and ask for prospective work ^[25]. It is the only evidence that dermal estriol has a measurable whole body consequence, and it is weak evidence, but it exists.

The general oestrogen cautions apply whatever the route. Estriol is a full agonist at both receptor subtypes and increases proliferation of oestrogen receptor positive breast cancer cells in culture to about the same extent as estradiol at matched concentrations ^[1], so a history of oestrogen sensitive cancer, current aromatase inhibitor or tamoxifen therapy, undiagnosed vaginal bleeding, active thromboembolic disease and pregnancy are all reasons not to start without a specialist agreeing first. Estriol stimulates melanocyte tyrosinase and melanin extrusion in culture ^[38][39], so worsening of melasma is a plausible facial risk that no estriol trial has measured. The only well controlled trial of a topical oestrogen on sun exposed facial skin, using estrone, induced matrix metalloproteinase-1 by 10.3 times ^[35]; whether estriol does the same is unknown. Local irritation, itching and redness are the ordinary complaints of any medicated cream and are not specific to this one. What is genuinely not known: no long term safety study of facial estriol exists, no trial has followed endometrium or breast in facial users, and the longest facial exposure with any hormonal monitoring at all is six months in 59 women.

Estriol was isolated from the urine of pregnant women around 1930 by Guy Frederic Marrian, which puts it among the first human steroid hormones ever purified. Outside pregnancy it barely registers; the placenta makes it in enormous quantity, which is why maternal estriol became a prenatal screening marker long before anyone put it on skin.

Its reputation as the mild oestrogen was earned in the rat uterus in the 1970s. Estriol was shown to translocate the receptor into the nucleus exactly as fast as estradiol and to drive the same early responses for the first three hours, but the complex was not retained past six hours and no true tissue growth followed, so a single dose of estriol antagonised estradiol ^[32][31]. The same programme produced the observation the entire topical field depends on: given continuously, estriol is retained at nuclear sites and acts as a full agonist ^[33].

The skin thread begins in Finland. Rauramo and Punnonen gave oral estriol succinate to castrated women through the 1970s and measured the epidermis rather than the symptoms, showing that it prevented the thinning seen in untreated controls ^[12][11]; they demonstrated oestrogen receptors in human skin in 1980 ^[14]; and in 1987 they applied oestriol to abdominal skin directly and reported thicker, better ordered elastic fibres in the papillary dermis ^[10].

The facial work, and the reason estriol appears in cosmetic contexts at all, is Austrian. Schmidt and colleagues in Vienna ran a pilot in 1994 and a 59 woman comparison in 1996, in both cases setting 0.3 percent estriol cream against 0.01 percent estradiol cream on the ageing face, and separately asked in 1993 whether an oestrogen ointment on the face had systemic effects ^[8][7][9]. They also extended the idea into acne scarring by iontophoresis in 1995 ^[19]. Nothing on that scale has been repeated with estriol since.

The field then moved on without it. Later trials of topical oestrogen for skin ageing used estradiol, conjugated oestrogens, estrone or phytoestrogens, and the industry eventually built soft oestrogens designed to be destroyed inside the skin so that no hormone reaches the blood at all. A 2026 systematic review in the Journal of the American Academy of Dermatology finally collected the topical oestrogen and skin ageing literature across estradiol, estriol, estrone and phytoestrogens ^[24]. Meanwhile estriol reappeared where nobody had licensed it: an analysis of 240 skincare products sold in China in 2025 found it in 73 of them, at concentrations the buyer had no way to know about ^[25].

Estriol has a longstanding reputation as the gentle estrogen, prized for a mild and sometimes tissue-selective action that makes it well suited to treating localized menopausal symptoms without the fuller systemic punch of estradiol. Its relative preference for one class of estrogen receptor and its behavior as a partial agonist mean it can provide relief while exerting a comparatively soft influence overall, which underlies its appeal for topical and vaginal use.

The intriguing link between the surge of placental estriol in pregnancy and the natural easing of multiple sclerosis has driven genuine scientific curiosity, and clinical trials have examined whether supplementing estriol can carry that benefit into treatment. It is fair to say that its role in autoimmune disease remains investigational and that estriol is still a true estrogen requiring appropriate medical oversight. Within its niche, however, it is regarded as a valued, well-tolerated option with an unusually rich physiological story behind it.